LaLonde J M, Zhao B, Smith W W, Janson C A, DesJarlais R L, Tomaszek T A, Carr T J, Thompson S K, Oh H J, Yamashita D S, Veber D F, Abdel-Meguid S S
Departments of Structural Biology, Protein Biochemistry, Physical and Structural Chemistry, Molecular Recognition, and Medicinal Chemistry, SmithKline Beecham Pharmaceuticals, Prussia, Pennsylvania 19406, USA.
J Med Chem. 1998 Nov 5;41(23):4567-76. doi: 10.1021/jm980249f.
Papain has been used as a surrogate enzyme in a drug design effort to obtain potent and selective inhibitors of cathepsin K, a new member of the papain superfamily of cysteine proteases that is selectively and highly expressed in osteoclasts and is implicated in bone resorption. Here we report the crystal structures of two papain-inhibitor complexes and the rational design of novel cathepsin K inhibitors. Unlike previously known crystal structures of papain-inhibitor complexes, our papain structures show ligand binding extending deep within the S'-subsites. The two inhibitor complexes, carbobenzyloxyleucinyl-leucinyl-leucinal and carbobenzyloxy-L-leucinyl-L-leucinyl methoxymethyl ketone, were refined to 2.2- and 2.5-A resolution with R-factors of 0.190 and 0. 217, respectively. The S'-subsite interactions with the inhibitors are dominated by an aromatic-aromatic stacking and an oxygen-aromatic ring edge interaction. The knowledge of S'-subsite interactions led to a design strategy for an inhibitor spanning both subsites and yielded a novel, symmetric inhibitor selective for cathepsin K. Simultaneous exploitation of both S- and S'-sites provides a general strategy for the design of cysteine protease inhibitors having high specificity to their target enzymes.
在药物设计工作中,木瓜蛋白酶被用作替代酶,以获得组织蛋白酶K的强效和选择性抑制剂。组织蛋白酶K是木瓜蛋白酶超家族半胱氨酸蛋白酶的新成员,在破骨细胞中选择性且高度表达,与骨吸收有关。在此,我们报道了两种木瓜蛋白酶-抑制剂复合物的晶体结构以及新型组织蛋白酶K抑制剂的合理设计。与先前已知的木瓜蛋白酶-抑制剂复合物晶体结构不同,我们的木瓜蛋白酶结构显示配体结合延伸至S'亚位点深处。两种抑制剂复合物,即苄氧羰基亮氨酰-亮氨酰-亮氨醛和苄氧羰基-L-亮氨酰-L-亮氨酰甲氧基甲基酮,分别精修至2.2埃和2.5埃分辨率,R因子分别为0.190和0.217。与抑制剂的S'亚位点相互作用主要由芳香-芳香堆积和氧-芳香环边缘相互作用主导。对S'亚位点相互作用的了解导致了一种跨越两个亚位点的抑制剂设计策略,并产生了一种对组织蛋白酶K具有选择性的新型对称抑制剂。同时利用S和S'位点为设计对其靶酶具有高特异性的半胱氨酸蛋白酶抑制剂提供了一种通用策略。